• Home
  • Artificial Intelligence
  • Cryptocurrencies
  • Technology
  • Gold
  • Stocks
    RedditBluesky
    • Home
    • Artificial Intelligence
    • Cryptocurrencies
    • Technology
    • Gold
    • Stocks
    Home » News » CBD stops coronavirus in test tube

    CBD stops coronavirus in test tube

    Does cannabis compound help against covid?

    Justin Wong (JW)May 8, 2025



    Initial research suggesting that a popular non-psychoactive compound derived from marijuana could help prevent or treat COVID-19 warrants further investigation in rigorous clinical trials, researchers say.

    Several recent laboratory studies of cannabidiol (CBD) have shown promising results and attracted media attention.

    However, many other potential COVID treatments that have shown promise in the test tube - from hydroxychloroquine to various drugs used to treat cancer and other diseases - have not shown benefit in clinical trials for COVID-19 patients.

    Marsha Rosner of the University of Chicago led a team that found that in laboratory experiments, CBD appeared to help contain SARS-CoV-2 in infected cells. "Our results do not suggest that this also works in patients. Our results support a clinical study," she said.

    Using small doses of highly purified CBD, roughly equivalent to what patients receive in an oral medication already approved for severe epilepsy, Rosner and colleagues found that CBD did not stop the coronavirus from infecting cells in the test tube.

    Rather, it worked shortly after the virus entered cells, preventing it from making copies of itself, in part by affecting the inflammatory protein interferon. According to a report in Science Advances, they found similar effects in infected mice.

    In a group of adults with severe epilepsy, the researchers found that those taking the approved CBD drug had fewer cases of COVID-19. However, a review of a small number of patients does not provide conclusive information. According to Rosner, only randomized clinical trials can do that.

    "I know my message is not what people want to hear," she said.

    Low doses of tetrahydrocannabinol (THC) - the marijuana ingredient that causes the high - cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabichromene (CBC) and cannabigerol (CBG) did not keep the virus away from cells or prevent it from multiplying , found her team.

    "Not only did THC not work, but combining it with CBD also prevented CBD from working," Rosner said.

    NO COVID REMEDIES IN CBD PHARMACY

    Another team recently reported in the Journal of Natural Products that high doses of CBG and CBDA prevent the coronavirus from entering cells.

    Richard van Breemen of Oregon State University told Reuters that the doses his team tested were not toxic to the cells. It's not yet clear if similarly high doses would be safe for humans, his team said.

    "You want the lowest possible effective dose," Rosner said of possible side effects since the drug is filtered through the liver.

    The CBD tested by her team was over 98% pure, while commercial products are far less pure. "People shouldn't run out and get CBD from their favorite pharmacy," she said.

    CBD products are now available in many forms and are touted as a remedy for pain and other ailments, often without clinical evidence.

    Small CBD studies in people with COVID-19 are underway.

    In a completed study, researchers in Brazil randomly assigned 105 patients with mild or moderate COVID-19 to receive CBD or a placebo for 14 days on top of standard care. According to a report in Cannabis and Cannabinoid Research in October, CBD had no apparent effect.

    In a proof-of-concept study at Sheba Medical Center in Israel, researchers randomly assign patients with mild COVID to CBD or a placebo.

    An early-stage study at Rabin Medical Center, also in Israel, aims to test the effects of CBD in severely or critically ill patients. The leader of the study, Dr. Moshe Yeshurun, however, told Reuters that finding participants was difficult because the current wave of coronavirus caused by Omicron "consists mainly of patients with mild to moderate illness".

    Rosner's team is currently exploring the possibility of a clinical trial that would likely focus on asymptomatic or mild cases of COVID. In the meantime, she's concerned that media reports overstating the potential of cannabinoids are tricking people into self-medicating with CBD, stopping wearing masks, and avoiding vaccinations.

    "We'd like to be able to say specifically that a certain dose of cannabinoids is helpful," she said, but as of this writing, "vaccine-induced antibodies and antibody drugs are much more effective at blocking infection."

    CBDCoronaForschung





    Disclaimer


    This report should not be viewed as investment advice or as an offer to buy or sell any securities or as an invitation or solicitation of an offer to buy or sell any securities. Neither the author of this report, its publisher, nor any other person associated with the publication of this report, are registered brokers, investment dealers, investment advisers, or financial advisers. The information in this report has not been tailored to the particular needs or circumstances of readers and should not be relied upon as investment advice or recommendations to purchase or sell any of the securities presented in this report. Readers seeking investment advice should contact qualified and registered brokers, investment dealers, investment advisers, or financial advisers prior to making any decision to buy or sell any of the securities referred to in this report. The information in this report should not be construed as investment, legal, or tax advice. No recommendation is made as to whether an investment in the presented securities is suitable for any reader in light of the reader’s particular circumstances.

    Readers are cautioned that the publisher of this report covers exclusively securities that carry a high degree of volatility. Investing in such securities is highly speculative and carries a high degree of risk. Investors in such securities could lose all or a substantial portion of their investment. Only those investors who can afford to lose all or a substantial portion of their investment should consider investing in the securities referred to in this report.

    This report may include information obtained from publicly available sources, including third-party reports or analysis. Neither the author nor publisher of this report, nor www.juniorstocks.com or its owners, have undertaken any independent investigation into the factual information used in this report, and the information in this report is provided without any warranty of any kind. No representations or warranties are provided regarding the accuracy or completeness of the information provided in this report. Statements of opinion or belief are those of the authors and/or publisher of this report. These statements of opinion or belief are expressions of the author’s and/or publisher’s judgment, and there is no guarantee that those judgments will turn out to be correct. No inference should be drawn that the author and/or publisher have any special or greater knowledge about the presented companies or their securities, or any particular expertise in the industries or markets in which the company operates. Readers should conduct their own due diligence and seek professional advice prior to investing in any securities presented on Juniorstocks.com.

    Certain statements in this report constitute “forward-looking” statements. Forward-looking statements often, but not always, are identified by the use of words such as “seek,” “anticipate,” “believe,” “plan,” “estimate,” “expect,” “targeting,” and “intend” and statements that an event or result “may,” “will,” “should,” “could,” or “might” occur or be achieved and other similar expressions. Forward-looking statements express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance; they are not statements of historical facts and should not be viewed as any guarantee of any future result. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. The author and/or publisher of this report disclaims any obligation to update the forward-looking statements in this report, whether as a result of new information, future events, or results or otherwise. There is no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

    The information provided in this report is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to applicable law or regulation, or would subject the author or publisher of this report to any registration requirement in such jurisdiction or country.

    Information about the editor of this publication:
    Juniorstocks.com is a service provided by Piccadilly Capital Group, Office 66, 101 Clapham High Street, London, SW4 7TB, UK. Piccadilly Capital Group is not the publisher of this report and was not paid for the publication of this report. Piccadilly Capital Group seeks to generate web traffic and a growing number of followers through the publication of articles or reports. Directors, officers, and other insiders of the publisher own an interest in Piccadilly Capital Group. Piccadilly Capital Group does not endorse or recommend the business, products, services, or securities of any company mentioned on www.juniorstocks.com. Piccadilly Capital Group will not share your information with any outside third parties. Due to the new data protection basic regulation, we ask you to read our data protection declaration carefully.

    Note on copyright:
    The contents published on this website and on connected media (e.g., e-mail, X, Facebook) are subject to applicable copyright and ancillary copyright laws. Any use not permitted by applicable copyright and ancillary copyright laws requires the prior written consent of the provider or the respective rights holder. In particular, this applies to the duplication, editing, translation, storage, processing, or reproduction of content in databases or other electronic media and systems. Contents and rights of third parties are marked as such. Unauthorized reproduction or transmission of individual contents or complete pages is not permitted and is punishable by law. Only the production of copies and downloads for personal, private, and non-commercial use is permitted. Links to the provider's website are always welcome and do not require the consent of the provider of the website. Photos and images on the website may not be shared unless the publisher itself has acquired the initial rights from authorized sources. The presentation of this website in external frames is only allowed with written permission. If you notice any violations, please inform us. Please note: The content of our articles, emails, or other publications or social networks such as X, LinkedIn or Facebook is exclusively intended for the designated addressee(s). If you are not the addressee of these articles, emails, or other publications in the market letter or social networks such as Twitter or Facebook or his or her legal representative, please note that any form of publication, reproduction, or distribution of the content of these articles, emails, or other publications in the market letter or social networks such as X, LinkedIn or Facebook is prohibited. Falsifications of the original content of this message during data transmission cannot be excluded in principle.


    Claw and Order: Antimony Rules the Resource Realm
    Read Next

    Claw and Order: Antimony Rules the Resource Realm

    • RIDE THE BULL

      Your Front Row Seat to the Stories That Move Markets. – Subscribe Now to our Newsletter!

    • Trending Now

      • Mario Vetro’s Axcap Ventures: Drilling Holes in Junior Mining’s Problems
        Mario Vetro’s Axcap Ventures: Drilling Holes in Junior Mining’s Problems
      • Stocks Pop as Trump Drops “Buy Now” Like It’s Hot
        Stocks Pop as Trump Drops “Buy Now” Like It’s Hot
      • The AI Tug-of-War: Can America Hold the Line Against China?
        The AI Tug-of-War: Can America Hold the Line Against China?
      • Bitcoin’s $99K Moonshot: Trump’s the Rocket Fuel
        Bitcoin’s $99K Moonshot: Trump’s the Rocket Fuel

    Claim Your Spot with Juniorstocks.com

    Unlock the stories that move markets directly in your inbox


    ContactDisclaimerData PrivacyTerms of Use
    • Bluesky
    • Reddit
    Copyright 2025 ©Juniorstocks.com - All Rights Reserved.
    Press enter/return to begin your search